Clinical trials: Chemoradiotherapy
Hilar Cholangiocarcinoma
Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma
Hilar cholangiocarcinoma is a highly malignant tumor. Surgical resection or simple liver transplantation leads to poor prognosis accompanied by high recurrence rate and low survival rate.
- Trial name
- NCT02178280
- Testing
- liver transplantation combined with neoadjuvant therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Lung Cancer
Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells.
- Trial name
- NCT00030810
- Testing
- Hyperfractionated, Taxotere/Cisplatin, conventional surgery
- Where
- Switzerland
- Volunteers
- 46 people
- Sponsor
- Swiss Cancer Institute
Esophageal Cancer
Simultaneous Integrated Boost (SIB) in Esophageal Cancer
The goal of this clinical research study is to find the highest tolerable dose of radiation that can be given in combination with chemotherapy in patients with esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT01102088
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric-type Endocervical Adenocarcinoma, Cervical Cancer
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma
Background: Gastric-type endocervical adenocarcinoma (G-EAC) is a new classification of cervical mucinous carcinoma. G-EAC is a unique human papillomavirus unrelated adenocarcinoma that can be distinguished from typical…
- Trial name
- NCT06870565
- Testing
- paclitaxel and platinum, platinum
- Volunteers
- 238 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Stage III Non-small Cell Lung Cancer
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and…
- Trial name
- NCT01102231
- Testing
- Chemotherapy, ERBITUX, Radiotherapy
- Where
- 38 sites in France
- Volunteers
- 106 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Cervical Cancer
A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix Cancer
Perspectives: To analyse if the change of specific immune response will correlate with clinical effect of advanced cervix cancer after radio-chemotherapy.
- Trial name
- NCT03559803
- Testing
- Cisplatin
- Where
- 2 sites in China
- Volunteers
- 58 people
- Sponsor
- Sichuan University
Lung Neoplasm, Cell Hypoxia
Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy
Non-small cell lung cancer (NSCLC) has a poor prognosis if not caught early enough. One of the factors that may impact the ability to control NSCLC is low oxygen levels (hypoxia) inside the tumour.
- Trial name
- NCT00765986
- Testing
- 18F-FAZA, 18F-Fluorodeoxyglucose (18F-FDG)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- AHS Cancer Control Alberta
Rectal Neoplasms
Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer
Neoadjuvant chemoradiation (CRT), is considered the standard treatment of locally advanced rectal cancer with a positive impact on locoregional control and survival.However, patients with T4 rectal cancer show high risk of local…
- Trial name
- NCT02723253
- Testing
- Radiotherapy, Tom-OX
- Volunteers
- 18 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Esophageal Cancer
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery.
- Trial name
- NCT03731442
- Testing
- Involved field irradiation, Elective field irradiation, Paclitaxel
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chinese Academy of Medical Sciences
Oesophageal Cancer
Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer
This is a feasibility study testing the use of the Cytosponge™ device in patients with known oesophageal cancer treated with pre-operative or definitive chemoradiation.
- Trial name
- CYTOFLOC (NCT03529669)
- Testing
- Cytosponge™
- Where
- 11 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Oxford
Cervical Cancer, Uterine Cervical Cancer
FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer
In this study, 50 evaluable patients will undergo one FDG-PET study during their chemoradiation, in addition to the standard of care pretreatment and 3-month post-treatment clinical FDG-PET/CT or FDG-PET/MR scans.
- Conditions
- Cervical Cancer, Uterine Cervical Cancer, Uterine Cervical Neoplasms
- Trial name
- NCT02317302
- Testing
- FDG-PET/MR, FDG-PET/CT
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Gynecologic Cancer
Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors
The two goals of this study are to establish a standardized method of assessing the pelvic floor for patients undergoing pelvic radiation and to determine the feasibility of inverse-RT planning using MRI to identify dosimetric…
- Trial name
- NCT05769062
- Testing
- Single digit pelvic exam
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington University School of Medicine
Limited Stage Small Cell Lung Cancer
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
This study is a multi-center, Single-arm Phase II study to evaluate the clinical efficacy and safety of Consolidation HLX10 (Serplulimab) Following Hypofractionated Radiotherapy With Concurrent Chemotherapy for Patients With…
- Trial name
- NCT05443646
- Testing
- HLX10, hypofractionated radiotherapy, Prophylactic Cranial Irradiation (PCI)
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC
This is a single-arm, open-label, single-center phase II trial that will enroll 30 patients with limited-stage small-cell lung cancer to evaluate the safety and efficacy of adebrelimab combined with chemoradiotherapy followed by…
- Trial name
- NCT07200154
- Testing
- Adebrelimab with concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cancer, Non Small Cell Lung Cancer
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients'…
- Conditions
- Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III, NSCLC
- Trial name
- DART (NCT04392505)
- Testing
- Durvalumab Injection
- Where
- 10 sites in Estonia, Finland and 2 more
- Volunteers
- 100 people
- Sponsor
- Oslo University Hospital
Locally Advanced Rectal Carcinoma, Circulating Tumor DNA
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
Rectal cancer still remains one of the most popular tumors, however, distance metastasis still remains as high as 30% and the long-term survival outcomes are still unsatisfying.
- Trial name
- CINTS-R (NCT05601505)
- Testing
- circulating tumor DNA
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Peking Union Medical College Hospital
Nasopharyngeal Carcinoma, Children
Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
1. To see the effect if a combination of induction chemotherapy followed by chemoradiotherapy works in treating children with advanced nasopharyngeal carcinoma(NPC).
- Trial name
- NCT03020329
- Testing
- Paclitaxel liposome, Cisplatin, 5-fu
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Rectal Cancer
Radiomics-based Artificial Intelligence System to Predict Neoadjuvant Treatment Response in Rectal Cancer
In this study, investigators utilize a radiomics prediction model to predict the tumor response to neoadjuvant chemoradiotherapy (nCRT) before the nCRT is administered for patients with locally advanced rectal cancer (LARC).
- Trial name
- MRAI-pCR (NCT04273477)
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Cervical Cancer Stage IV
A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
Cervical cancer is one of the most malignant reproductive system tumors that threaten women's health, characterized by distinct HPV-driven carcinogenesis and immunosuppressive tumor microenvironment.
- Trial name
- NCT06998394
- Testing
- AK104 - Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiangbo Wan
Nasopharyngeal Carcinoma
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
This is an open, multicenter phase Ⅱ clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cetuximab (C225) combined with IMRT + neoadjuvant chemotherapy in advanced T stage of nasopharyngeal…
- Trial name
- REPLACE (NCT01271439)
- Testing
- Cetuximab
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.